Evonik and evitria launch eviCHO CHO‑K1 transient expression kit
- eviCHO Expression Kit: ready-to-use transient protein expression system based on CHO‑K1 cells.
- Kit supplies ready components and commercially validated protocols to speed and standardise transient expression workflows.
- evitria has performed over 125,000 transfections and expressed/purified more than 25,000 antibodies and antibody-based molecules.
- Partnership strengthens Evonik’s Advance Precision Biosolutions strategy; Evonik also partnered with InVitria in 2025 to add rHSA.
Product
Evonik and evitria have launched the eviCHO Expression Kit, a ready-to-use transient protein expression kit built on CHO‑K1 cells for biopharmaceutical research and development.
Technical benefits
The kit provides ready components and commercially proven protocols to simplify CHO transient expression workflows, reduce troubleshooting, and enable faster, more consistent transient protein production for early-stage studies that avoid stable cell line generation.
evitria capability
evitria, based in Zurich, specialises in CHO-based transient antibody expression and reports more than 125,000 transfections and over 25,000 antibodies and antibody-based molecules expressed and purified. The company serves academic, emerging biotech and large biopharma customers across the Americas, Europe, Asia and Australia.
Strategic context
The collaboration expands Evonik’s portfolio within its Advance Precision Biosolutions growth field and broadens access to evitria’s expertise for Evonik’s biopharma customers. In 2025 Evonik also partnered with InVitria to add recombinant human serum albumin (rHSA) to its offering, complementing its non-animal-derived ingredients for biomanufacturing such as amino acids, dipeptides, lipids and surfactants.
Source: Evonik
